Noxopharm Ltd
NOX
Company Profile
Business description
Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.
Contact
60 Linksley Avenue
GlenhavenNSW2156
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
17
Stocks News & Analysis
stocks
ASX share undervalued despite margin woes
Short term margin pressure yet shares remain undervalued on improved outlook.
stocks
A better way to predict long-term stock returns
A value-weighted version of the CAPE ratio corrects a structural flaw and delivers stronger forecasts of long-term stock returns.
stocks
Five star stock added to August best ideas list
Morningstar analysts hand pick this undervalued opportunity for their August global best ideas.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,849.30 | 74.60 | -0.84% |
| CAC 40 | 8,090.28 | 27.50 | -0.34% |
| DAX 40 | 25,402.28 | 38.53 | -0.15% |
| Dow JONES (US) | 52,055.18 | 366.02 | -0.70% |
| FTSE 100 | 10,658.13 | 39.44 | -0.37% |
| HKSE | 24,667.24 | 250.36 | -1.00% |
| NASDAQ | 25,970.73 | 215.69 | -0.82% |
| Nikkei 225 | 63,484.10 | 8.89 | -0.01% |
| NZX 50 Index | 13,484.22 | 76.47 | -0.56% |
| S&P 500 | 7,582.73 | 37.25 | -0.49% |
| S&P/ASX 200 | 8,672.50 | 77.40 | -0.88% |
| SSE Composite Index | 3,864.28 | 21.05 | -0.54% |